2023 - Research.com Medicine in Switzerland Leader Award
The scientist’s investigation covers issues in Internal medicine, Transplantation, Surgery, Hematopoietic stem cell transplantation and Immunology. His Internal medicine research includes elements of Gastroenterology and Oncology. His Oncology research is multidisciplinary, relying on both European LeukemiaNet and Imatinib mesylate.
His work carried out in the field of Transplantation brings together such families of science as Retrospective cohort study, Chronic myelogenous leukemia, Stem cell and Bone marrow. His research in Surgery focuses on subjects like Multiple myeloma, which are connected to Autogenous bone and Marrow transplantation. The study incorporates disciplines such as Hematopoietic stem cell, Cord blood and Hazard ratio in addition to Hematopoietic stem cell transplantation.
His primary areas of study are Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Immunology and Surgery. He has included themes like Gastroenterology and Oncology in his Internal medicine study. Alois Gratwohl interconnects Imatinib and Myeloid leukemia in the investigation of issues within Oncology.
His research investigates the connection with Transplantation and areas like Stem cell which intersect with concerns in Cord blood. Alois Gratwohl combines subjects such as Hematopoietic stem cell, Framingham Risk Score, Cohort and Intensive care medicine with his study of Hematopoietic stem cell transplantation. Much of his study explores Immunology relationship to Cytotoxic T cell.
Alois Gratwohl mostly deals with Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Surgery and Oncology. Internal medicine and Gastroenterology are frequently intertwined in his study. His Transplantation research is multidisciplinary, incorporating perspectives in Haematopoiesis, Stem cell and Pediatrics.
His biological study spans a wide range of topics, including Retrospective cohort study, Immunology, Cohort and Intensive care medicine. The various areas that he examines in his Surgery study include Immunosuppression and Hazard ratio. Alois Gratwohl has researched Oncology in several fields, including Blast Phase, Multiple myeloma and Drug.
His primary areas of investigation include Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Surgery and Immunology. His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine. His Transplantation research is multidisciplinary, incorporating elements of Unrelated Donor, Haematopoiesis, Cord blood and Intensive care medicine.
His studies in Hematopoietic stem cell transplantation integrate themes in fields like Hematopoietic stem cell, Cohort and Hazard ratio. His research ties Oncology and Surgery together. The Immunology study combines topics in areas such as Transplantation Conditioning, Toxicity and Haplotype.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten.
The New England Journal of Medicine (2009)
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
A. Gratwohl;J. Hermans;J. Goldman;W. Arcese.
The Lancet (1998)
Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow Transplantation
E.A.J.M. Goulmy;R. Schipper;J. Pool;E. Blokland.
The New England Journal of Medicine (1996)
Hematopoietic stem cell transplantation: a global perspective
Alois Gratwohl;Helen Baldomero;Mahmoud Aljurf;Marcelo C. Pasquini.
IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE
Rowlings Pa;Przepiorka D;Klein Jp;Gale Rp.
British Journal of Haematology (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: